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suggests ZIKV as the primary flavivirus infection. 
The limited antibody response in Patient 2 was 
presumably due to her ongoing immunosuppres-
sive therapy. Although neither patient reported 
symptoms associated with ZIKV infection dur-
ing the investigation, these data show evidence 
for ZIKV transmission by means of platelet 
transfusion.
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Treatment Outcomes in Multidrug-Resistant Tuberculosis
To the Editor: Despite lengthy treatment with 
costly second-line drug regimens, curing multi-
drug-resistant (MDR) tuberculosis (bacillary resis-
tance to at least isoniazid and rifampin) remains 
a challenge.1 The World Health Organization 
(WHO) defines “cure” as “treatment completion” 
with at least three negative cultures after the 
intensive phase of therapy in the absence of 
“treatment failure.” The definition of “treatment 
failure” requires early termination of treatment 
or the need for permanent regimen change of at 
least two antituberculosis drugs. “Treatment 
success” is defined as the sum of cure and treat-
ment completion.2
We evaluated treatment outcomes according 
to WHO definitions in the TBNET cohort of 380 
patients with MDR tuberculosis at 23 European 
centers, including 89 patients with pre–extensively 
drug-resistant (XDR) tuberculosis and 33 patients 
with XDR tuberculosis,3,4 and compared them 
with simplified definitions of MDR tuberculosis 
treatment outcomes (see the Supplementary Ap-
pendix, available with the full text of this letter 
at NEJM.org). Cure was defined as a negative 
culture status 6 months after treatment initiation, 
no positive culture thereafter, and no relapses 
within 1 year after treatment completion. Treat-
ment failure was defined as a positive culture 
status 6 months after treatment initiation or 
thereafter or a relapse within 1 year after treat-
ment completion. An undeclared outcome was 
defined as an outcome that was not assessed 
(owing to transferral out of the cohort, no cul-
ture status at 6 months while the patient was 
receiving care, or no post-treatment assessment). 
Death was defined as death during observation. 
Loss to follow-up was defined as nonreceipt of 
care 6 months after treatment initiation.
Fifty of 88 patients with treatment failure 
(57%) were not identified by the WHO defini-
tion. Assessment of WHO-defined cure was pos-
sible for only 13% of the patients in countries 
with a low incidence of tuberculosis (with a noti-
fication rate <20 per 100,000 population), 58% 
of the patients in countries with an intermediate 
incidence (with a notification rate of 20 to 100 per 
100,000 population), and 52% of the patients in 
countries with a high incidence (with a notifi-
cation rate >100 per 100,000 population), owing 
to a lack of sputum cultures obtained after the 
intensive-treatment phase. This could reflect the 
limited access to health care of mostly foreign-
born patients or the inability of patients to pro-
duce sputum in the latter stages of therapy. 
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WHO-defined treatment success in MDR tuber-
culosis is predominantly driven by completing 
treatment rather than by a biologic end point 
and fails to address relapse-free survival as a 
clinically more relevant assessment of treatment 
efficacy.
Relapse-free cure was achieved in 61% of the 
patients with MDR tuberculosis, 52% of the pa-
tients with pre-XDR tuberculosis, and 39% of 
the patients with XDR tuberculosis when simpli-
fied definitions were used, in contrast to WHO-
defined cure in 31%, 27%, and 24% of patients, 
respectively (Fig. 1).
Of the 318 patients with a negative culture 
status at 6 months, 35 (11%) reverted in the 
continuation phase, and 9 (3%) had a post-
treatment relapse, findings that suggest that 
culture status at 6 months may be a reliable 
predictor of relapse-free cure in patients with 
MDR tuberculosis.5
In conclusion, current WHO definitions may 
underestimate cure in patients with MDR tuber-
culosis. These definitions could be simplified 
while incorporating the assessment of post-
treatment relapse.
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Figure 1. Culture Conversion, Subsequent Reversion, and Outcomes of Tuberculosis Treatment According to Simplified 
and WHO Definitions.
Panel A shows culture conversion to negative cultures in all patients with a positive culture at the start of second-line 
treatment for tuberculosis. Panel B shows reversion to positive cultures in patients in whom culture conversion oc-
curred during the study. Panel C shows final outcome according to proposed simplified definitions. Panel D shows 
final outcome according to World Health Organization (WHO) definitions. Multidrug-resistant (MDR) tuberculosis 
was defined as bacillary resistance to at least isoniazid and rifampin but excluding pre–extensively drug-resistant (XDR) 
tuberculosis and XDR tuberculosis. Pre-XDR tuberculosis was defined as bacillary resistance to isoniazid and rifampin 
and either any fluoroquinolone or any second-line injectable drug. XDR tuberculosis was defined as bacillary resis-
tance to isoniazid and rifampin, any fluoroquinolone, and any second-line injectable drug (amikacin, capreomycin, 
or kanamycin).
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